Bill would prevent drug makers from thwarting generic competition #pharmaceutical #manufacturing #companies

Posted On Aug 28 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


XPRIZE Home Page #xprize, #x-prize, #foundation, #nonprofit, #incentive, #prize, #competition, #grand-challenges

Posted On Aug 13 2017 by

# To Build a Bridge to Abundance for All We are XPRIZE. We are the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. We believe that inherent to every individual on the planet is a creative, entrepreneurial and inventive spirit, and as a global community – or crowd – we can activate this ingenuity and create innovation to collectively solve the Earth’s most pressing problems. We are XPRIZE. We are the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. We believe that inherent to every individual …


Bill would prevent drug makers from thwarting generic competition #pharmaceutical #companies #india

Posted On Aug 9 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


Generic pharmaceuticals and competition #biotech #pharma #jobs

Posted On Aug 4 2017 by

#generic pharmaceutical # Competition Generic pharmaceuticals and competition Entry by generic pharmaceuticals can enhance competition in the drug market by offering more choice and by lowering drug prices to the benefit of health customers. At the same time, innovation in the pharmaceutical sector should be sustained, notably by allowing innovators to obtain intellectual property rights on their originator drug. Competition concerns arise, however, when originator companies use their intellectual property rights to delay or to prevent generic entry. Some pharmaceutical companies are using new potentially anticompetitive strategies. In June 2014 meeting, the OECD Competition Committee addressed recent developments regarding such …


Bill would prevent drug makers from thwarting generic competition #marketing #pharmaceuticals

Posted On Aug 2 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


Generic pharmaceuticals and competition #capricorn #pharma

Posted On Jul 12 2017 by

#generic pharmaceutical # Competition Generic pharmaceuticals and competition Entry by generic pharmaceuticals can enhance competition in the drug market by offering more choice and by lowering drug prices to the benefit of health customers. At the same time, innovation in the pharmaceutical sector should be sustained, notably by allowing innovators to obtain intellectual property rights on their originator drug. Competition concerns arise, however, when originator companies use their intellectual property rights to delay or to prevent generic entry. Some pharmaceutical companies are using new potentially anticompetitive strategies. In June 2014 meeting, the OECD Competition Committee addressed recent developments regarding such …


Bill would prevent drug makers from thwarting generic competition #pharmaceutical #companies #list

Posted On Jul 10 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


Generic pharmaceuticals and competition #top #ten #pharmaceutical #companies

Posted On May 2 2017 by

#generic pharmaceutical # Competition Generic pharmaceuticals and competition Entry by generic pharmaceuticals can enhance competition in the drug market by offering more choice and by lowering drug prices to the benefit of health customers. At the same time, innovation in the pharmaceutical sector should be sustained, notably by allowing innovators to obtain intellectual property rights on their originator drug. Competition concerns arise, however, when originator companies use their intellectual property rights to delay or to prevent generic entry. Some pharmaceutical companies are using new potentially anticompetitive strategies. In June 2014 meeting, the OECD Competition Committee addressed recent developments regarding such …


Bill would prevent drug makers from thwarting generic competition #par #pharma

Posted On Apr 11 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …


Bill would prevent drug makers from thwarting generic competition #d #pharma

Posted On Apr 3 2017 by

#generic drug companies # Lawmakers look to prevent drug makers from thwarting generic competition For the third time in less than two years, congressional lawmakers have introduced a bill designed to end a practice that generic drug makers say is used by brand-name rivals to thwart competition. Known as the Creating and Restoring Equal Access to Equivalent Samples Act, the bipartisan legislation comes amid ongoing complaints that brand-name drug makers sometimes refuse to provide samples to generic companies. They need samples to prove their copycat versions are equivalent to the brand-name drugs in order to pass regulatory muster. And the …